Your browser doesn't support javascript.
loading
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRASG12D Inhibitor.
Wang, Xiaolun; Allen, Shelley; Blake, James F; Bowcut, Vickie; Briere, David M; Calinisan, Andrew; Dahlke, Joshua R; Fell, Jay B; Fischer, John P; Gunn, Robin J; Hallin, Jill; Laguer, Jade; Lawson, J David; Medwid, James; Newhouse, Brad; Nguyen, Phong; O'Leary, Jacob M; Olson, Peter; Pajk, Spencer; Rahbaek, Lisa; Rodriguez, Mareli; Smith, Christopher R; Tang, Tony P; Thomas, Nicole C; Vanderpool, Darin; Vigers, Guy P; Christensen, James G; Marx, Matthew A.
Afiliación
  • Wang X; Mirati Therapeutics, San Diego, California 92121, United States.
  • Allen S; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Blake JF; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Bowcut V; Mirati Therapeutics, San Diego, California 92121, United States.
  • Briere DM; Mirati Therapeutics, San Diego, California 92121, United States.
  • Calinisan A; Mirati Therapeutics, San Diego, California 92121, United States.
  • Dahlke JR; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Fell JB; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Fischer JP; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Gunn RJ; Mirati Therapeutics, San Diego, California 92121, United States.
  • Hallin J; Mirati Therapeutics, San Diego, California 92121, United States.
  • Laguer J; Mirati Therapeutics, San Diego, California 92121, United States.
  • Lawson JD; Mirati Therapeutics, San Diego, California 92121, United States.
  • Medwid J; Mirati Therapeutics, San Diego, California 92121, United States.
  • Newhouse B; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Nguyen P; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • O'Leary JM; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Olson P; Mirati Therapeutics, San Diego, California 92121, United States.
  • Pajk S; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Rahbaek L; Mirati Therapeutics, San Diego, California 92121, United States.
  • Rodriguez M; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Smith CR; Mirati Therapeutics, San Diego, California 92121, United States.
  • Tang TP; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Thomas NC; Mirati Therapeutics, San Diego, California 92121, United States.
  • Vanderpool D; Mirati Therapeutics, San Diego, California 92121, United States.
  • Vigers GP; Pfizer Boulder Research & Development, Boulder, Colorado 80301, United States.
  • Christensen JG; Mirati Therapeutics, San Diego, California 92121, United States.
  • Marx MA; Mirati Therapeutics, San Diego, California 92121, United States.
J Med Chem ; 65(4): 3123-3133, 2022 02 24.
Article en En | MEDLINE | ID: mdl-34889605
Asunto(s)
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Proteínas Proto-Oncogénicas p21(ras) / Antineoplásicos Tipo de estudio: Diagnostic_studies Límite: Animals / Humans Idioma: En Revista: J Med Chem Asunto de la revista: QUIMICA Año: 2022 Tipo del documento: Article País de afiliación: Estados Unidos